This Week in Cardiology Nov 07, 2025 This Week in Cardiology
18 snips
Nov 7, 2025 A fascinating discussion unfolds around non-culprit PCI in STEMI, highlighting critical listener feedback. Major cardiovascular benefits from omega-3 in hemodialysis patients are revealed in the PISCES trial. Exciting news on GLP-1 drugs surfaces as a new White House deal aims to enhance access. The podcast critiques the intriguing, yet dubious, results of the LAMP trial. Finally, a preview of pivotal upcoming AHA trials promises to shake up cardiology discussions, making this a must-listen for healthcare professionals.
AI Snips
Chapters
Transcript
Episode notes
Complete Revascularization Evidence Is Mixed
- Trials of complete revascularization in STEMI give mixed signals and may be driven by procedural MI and biased endpoints.
- John Mandrola argues the evidence does not clearly support routine non‑culprit PCI at the time of STEMI for stable lesions.
Listener From Wales Urges Nuance
- A listener from Wales argued stenosis severity and physiology screens sometimes randomly pick up unstable plaques, suggesting nuance.
- Mandrola concedes trials give average effects and specific scenarios warrant targeted study.
Fish Oil Showed Major Benefit In Dialysis
- The PISCES trial showed a large, significant reduction in major CV events with omega‑3 supplementation in hemodialysis patients.
- Mandrola finds the effect size surprising but believes the evidence justifies starting fish oil in dialysis patients pending confirmation.